The Eclipse Diagnostics offering is now closed and is no longer accepting investments.

Eclipse Diagnostics

Preventing Stroke At Home

Regulation Crowdfunding
​Los Angeles, CA
Biotechnology
Accepting International Investment
Play video

Just launched! Our next Reg CF Offering is now live.

Click here to learn more!

Preventing Stroke at Home

Invest in Eclipse Diagnostics

We are developing an easy-to-use home test to monitor the risk of stroke. The device is based on our patented technology, based on biomarker detection that is accurate, low cost and simple to use.


Each year nearly 800,000 people in the U.S. experience a new or recurrent stroke, and stroke is the fifth leading cause of death in the U.S. Up to 80 percent of strokes can be prevented, and our mission is to give surviving stroke patients, diabetics, and others a home testing device that can give an early warning sign and help prevent stroke at home.

Stroke Screening Home Test

Take control of your health from the comfort of your home

One-time-use, disposable test 

Simple-to-use test cartridge that is used like a glucose test strip or pregnancy test. All that's needed is a drop of blood. 

Bluetooth-enabled reader

The reader enables an accurate readout of the test in 15 minutes and transfers the data to the mobile application.

Mobile application

Portal for users to monitor their stroke risk status, which enables communication with one's doctor or relatives.

"All it takes is a drop of blood and 15 minutes."

"Stroke runs in my family and that drives me to bring a solution to market that can prevent it!

- Luka Fajs, Founder and CEO

Business Model

We will offer our solution direct to consumers using a subscription model that's based on a user's needs and health status.

Casual

$60

per month

free reader

free mobile app

4 tests/month

Basic

$99

per month

free reader

free mobile app

8 tests/month

Monitor+

$160

per month

free reader

free mobile app

15 tests/month

Global stroke management market

Expected to reach $36b by 2023

Growing at a CAGR of 7.1% (2017-2023)

Disrupting Traditional Industry

How big is the opportunity?

It's huge.  Our target consumers are stroke survivors and diabetics. In the U.S. alone there are 6.5 million stroke survivors (data from National Stroke Association) and over 10 million diabetics over 40-years old (data from CDC). Considering only the basic subscription model, this amounts to a market opportunity of $9.9 billion per year.


In-vitro diagnostics

$46B

(BCC Research; November 2015; IVD: Technologies and Global Markets)

Point-of-care diagnostics

$19B

(BCC Research; November 2016; “Point of Care Diagnostics)

Technological Breakthrough that Enables Affordable Home Testing

The core of our stroke home test is our patented testing platform - ELLI - that enables measurement of the levels of disease biomarkers within 15 minutes using only a drop of blood and a single-step procedure. How did we achieve that? We combined the underlying technologies of the two most successful tests in the market: pregnancy-test technology and the glucose-test technology. We merged them together with our patented chemical formulation that enables low-cost production and laboratory-grade accuracy.


The technology originates from Prof. Robert S. Marks's laboratory in the Ben-Gurion University of the Negev in Israel. We later proved the concept of the technology in Singapore in the laboratory of Prof. Marks and received several research grants to bring it to a stage, where we were able to prove its utility as a rapid and easy-to-use test for detection of stroke biomarkers, infectious disease, and other medical conditions.

History

The technology was first developed in Prof. Robert S. Marks's laboratory in the Ben-Gurion University of the Negev in Israel and further developed in Singapore with funding from the Singapore-MIT Alliance for Research and Technology (SMART), the National Research Foundation and SPRING Singapore. 


The company that was spun-out (Biosensorix - founded by Robert and Luka) and continued to develop and improve the performance of the technology and to develop several applications ranging from detection of infectious disease, male fertility, heart disease and stroke diagnostics.

The technology received several awards including:

  • Most Investible Team at InnovFest Unbound 2017
  • Most Disruptive Technology Innovfest Unbound 2017
  • Rockstar Pitch Innovfest Unbound 2017
  • Winner at the Singapore Airshow Exhibition Startup Competition 2018
  • 3rd prize at TechCrunch 2017 in Shanghai.

First prototype

Stage of the Technology Today

Working prototypes and technology that are on par with laboratory-based testing

We have developed several versions of our laboratory prototypes and have tested them with several target medical applications ranging from infectious disease, male fertility, heart markers and, of course, our target stroke biomarker. We have shown that the technology is highly sensitive and specific. The sensitivity and specificity of our tests are linked mainly to the source of antibodies we use for the detection - we use off-the-shelf, commercial antibodies that have been validated by others. Our innovation is to bind them in our patented testing platform, that enables rapid and accurate measurement of the biomarker levels. For now, we do not focus on antibody production or biomarker discovery. We use validated and known markers and apply them in our technology.

How do we intend to prevent stroke?

We measure a heart failure blood marker that, when elevated, indicates a high risk of stroke. A weakened heart cannot pump blood efficiently, and that can lead to the formation of blood clots that can cause a stroke. With continuous monitoring - at least once a week - we will be able to provide an early warning sign and recommend a visit to a physician who will provide the final diagnostics and treatment. Our stroke screening test is NOT intended to be a substitute for professional medical advice, diagnosis, or treatment. Always talk to your doctor or other healthcare provider about any questions you have about medical conditions. (source: Biosensors)

Stroke is the second leading cause of death worldwide

and it can happen to anyone anywhere

6+ million

deaths

16+ million

new strokes per year

5+ million

permanently disabled

Stroke can be prevented

Up to 80 percent of strokes can be prevented. Risk of stroke can be reduced by lowering blood pressure, losing weight, exercising, treating diabetes, treating atrial fibrillation, quitting drinking, and quitting smoking. These are all effective ways to reduce the risk of stroke, but today there is no way to assess and monitor the risk of stroke at home. (American Stroke Association)


We aim to do just that. Our solution is to monitor the risk of stroke using a simple-to-use blood test, similar to the glucose test used by diabetic patients. This was not available up to now because there was no affordable way to measure disease markers at home. Our technology enables that.

With a rapidly aging population and increased incidence of cardiovascular disease, stroke is becoming one of the leading causes of morbidity and mortality in the U.S. and across the world. 


A stroke is a "brain attack". It can happen to anyone at any time. It occurs when blood flow to an area of the brain is cut off. When this happens, brain cells are deprived of oxygen and begin to die. When brain cells die during a stroke, abilities controlled by that area of the brain such as memory and muscle control are lost.


How a person is affected by their stroke depends on where the stroke occurs in the brain and how much the brain is damaged. For example, someone who had a small stroke may only have minor problems such as temporary weakness of an arm or leg. People who have larger strokes may be permanently paralyzed on one side of their body or lose their ability to speak. Some people recover completely from strokes, but more than two-thirds of survivors will have some type of disability.


After experiencing a stroke, survivors and their families usually concentrate their efforts on rehabilitation and recovery. However, preventing a second stroke from happening is also critical. In the U.S. stroke kills more than 130,000 people each year. About 40 percent of deaths occur in males and 60 percent in females. About 25% of the nearly 800,000 strokes that occur each year are recurrent events. 


(American Stroke Association)

Who benefits the most?

Stroke survivors and diabetic patients are at the highest risk of stroke and are therefore the main groups that we want to reach. Our stroke screening test still requires a blood prick, and that is often a barrier for a number of healthy people. However, this is not the case with people who have experienced the terrifying consequences of stroke and also with diabetic patients who have to do a daily blood pricks to monitor their glucose levels.

Stroke survivors

Diabetic patients

Work to Be Done

Product Development & Regulatory Approval

We have successfully built and tested our first prototypes in a controlled laboratory environment. We are still assembling and manufacturing the devices in our laboratory and now need to move towards a controlled and optimized manufacturing with proper quality control. Translation of our initial product design to manufacturing will require a degree of additional research and development in order to maximize the design and manufacturing efficiency. We are also developing the second generation hand-held reader that will be Bluetooth enabled and will be able to communicate with the mobile application that we are yet to build. Our goal is to achieve these development goals within 18 months, which is when we will submit documentation to the FDA for regulatory approval. Based on initial discussions with FDA consultants we estimate that a 510k submission will be sufficient and that the process should take one year.

Do we have FDA approval yet?

We do not yet have FDA approval, but we are in early discussions with FDA consultants.

Do we need FDA approval?

Based on initial assessment with regulatory advisors we need to file a 510k premarket notification for a Class II screening device.

How long will it take?

Conditional we achieve all our R&D targets in time and 510k submission is sufficient, we estimate we can get the approval within 3 years.

Made in America for Americans

Our goal is to develop, manufacture and sell our Stroke Screen home test in the U.S.A. We want to support local industry and workers and bring a product of highest quality to market. Our intention is also to market the product first in the U.S. as per commitment form FDA to make the U.S. market a top priority for most developers of novel devices by the end of 2020. Today, many medical device companies target Europe first before setting their sights on FDA approval, thereby depriving U.S. patients of leading-edge products.

Our Competitive Advantage

Today, the main gap in the market of point-of-care (POC) devices lies in the detection of disease markers other than simple blood chemistry and electrolytes and glucose. Immunoassays are more complicated. Those molecules are currently identified using laboratory-based ELISA (enzyme-linked immunosorbent assay). Another benefit of current ELISA tests is that they offer both qualitative and quantitative results.


Many attempts have been made to “transfer” ELISA to POC, mostly utilizing expensive optics or microfluidics-based technologies. Immunoassays are also more challenging because they require proteins to interact and bind to each other and they require a wash cycle. The washing step is the main reason why most of today’s approaches use some kind of microfluidic mechanism - that in turn increases the cost and reduces the robustness of the tests.


To the best of our knowledge, our technology is the only one that enables truly affordable measurement of biomarker levels at home. Namely, most other competing approaches rely on detection and quantification of biomarkers using optics, spectroscopy, fluorescence, chemiluminescence or visualization of test band using a camera. While the underlying technologies are often very sensitive and reliable, their main barrier is the high cost of the readers that are typically over $1000. Moreover, they are often bulky and not suitable for home use. 


We have created our technology with the end user in mind. We wanted to develop something that is both easy to use, affordable and at the same time of laboratory-grade quality and precision.


Point-of-care diagnostics and diagnostics markets are widely recognized as markets with a high barrier of entry due to the concentration of the markets and dominance by big multinational diagnostic companies such as Roche, Abbott, Alere, BD Diagnostics, BioMérieux and others. Development of novel diagnostics is associated with high research and development costs that compound the barriers of entry.


However, the existing diagnostic market is shifting towards the idea of recentering diagnostics on people, rather than using the widespread centralized diagnostic laboratory model. As reported in Nature Biotechnology: “Investors are pumping money into start-ups chasing the holy grail of finger-prick diagnostics, and big players keep on acquiring innovators in the space." (Nature Biotech)


Here lies the key to lowering the perceived high-barrier of entry by employing the business strategy of bringing a product to a stage where the ‘big players’ are incentivized to take-over, acquire or license the technology. 


Our technology serves this niche market because we can provide laboratory-grade performance at a price that is accessible to a general consumer.

Data, Data, Data, Data

The greatest value beyond preventing stroke is the continuous health data.

We will collect the anonymized data to drive new research, machine learning and to provide novel health insights to our users. This will drive our business growth. We are developing an Internet-of-Things-enabled medical device that you will be able to embed in your smart home.

Decentralising Healthcare

Preventing stroke is just the begining

Stress management

Military applications

Athlete recovery

Fertility

Team of Top Talent

Dr. Luka Fajs (Feiss)

Founder and CEO

Luka comes from Slovenia and holds a PhD in Medical Microbiology. Before starting the company he was doing research and clinical laboratory diagnostics of hemorrhagic fevers, biothreats and other infectious diseases. He spent a lot of time in the field, helping doctors and nurses in low-income countries to set up and improve their diagnostic preparedness. During his work, he saw firsthand the drawbacks of the existing medical diagnostics system that is mostly centralized, capital-intensive, with many people not enjoying adequate access to it. That was the motivation to join Prof. Robert's laboratory in Singapore where he took over the fundraising and startup activities of the technology. He continued as CEO of Biosensorix and helped secure early funding and directed the research and development activities. He is a passionate entrepreneur with deep knowledge of diagnostics, user expectations, and basic science.

Prof. Robert S. Marks

Founder and Chief Scientist

Prof. Dr. Robert S. Marks is the co-inventor of the technological platform and is a renowned expert and key opinion leader in the field of biosensors. He is a Full Professor at the Ben-Gurion University of the Negev, Israel, at the Department of Biotechnology Engineering, The National Institute for Biotechnology in the Negev and the Ilse Kats Centre for Nanotechnology. He is presently a Visiting Scientist in the NTU-MSE, and was a program coordinator for the NRF CREATE program “Nanomaterials for Water and Energy Management”. Robert has previously co-founded Biosensing Technologies Ltd, Biopixel Ltd and Polyrizon Ltd. He will be assisting with advising the development of the next generation prototype and establishing the business collaboration with potential partners. Prof. Marks has extensive experience in development of biosensors. He is the Editor-in-Chief of a 2007 2-volume Wiley Handbook in Biosensors and Biochips and a 2014 Viral Diagnostics book for virus detection. He is the author of 150+ papers (H-index 27), and numerous chapters. He has 4 issued patents as well as a dozen filed.

Tina Semolic

Marketing

Head of Marketing

Previously at Adglow.com (clients: Prada, Miu Miu, Moschino, Pinko, Max Mara, Armani ect.), Httpool.com (over 50 clients: Generali insurance, Mercedes, Audi, STO - Slovenian touristic org. ect.), Adroll.com (Head of Business Development SMB) Facebook.com (over 500 clients: Adidas, Nike, Ferrari, illy, Morellato, Fossil, Head, Hugs ect.)

Đina Mandic

Marketing

Social Media Marketing Manager

Currently at Đina's Real Estate Agency. Đina is an experienced salesperson and marketer with a passion for social media and PR.

Advisors

Dr. Joseph Mocanu

Joseph is a founding partner at Verge Capital Singapore, and was a Principal in Oliver Wyman’s Singapore office, leading life sciences and digital health across Asia, sits on the Advisory Board of Galen Growth Asia and is a startup mentor at the Singapore Institute of Management.

Branka Palic

BSc in Medical Technology/MSc in Molecular Biology with 20 + years of experience in directing and managing Clinical Trials and Clinical Operations previously at Roche, currently at Bayer. Directed and managed clinical trials Phase II –IV in HIV/HVC Co-infected patients, HIV, HCV, Cardiology, Urology and Women’s Health and currently Phase I trials in Chagas disease.

John Molyneux

VP Manufacturing Operations at TriReme Medical, LL. Previously at Abbott (i-STAT).

//Geek section

The proof-of-principle has been previously demonstrated with a model protein. The immunoassay research comprised of an immunocomplex between antigen NS1 protein and NS1 antibody conjugated onto the immuno-nanobeads. Applying a running buffer, the immunocomplexes flowed to the immuno-conjugated SPGE surface and formed a specific sandwich detection due to biomolecular recognition. The immunocomplex formation was successfully analysed by electrochemical detection. An electrochemical signal due to the specific detection of NS1 was contributed by a redox label functionalised on the bead containing the NS1 antibody. A proportional increase of faradic current with the increase of the analyte NS1 protein concentration was observed. The ELLI prototype was assembled in a cassette and it successfully demonstrates a linear response over a concentration range of 1–50 ng/mL with an R2 of 0.928. The specificity of the NS1 protein detection system was investigated. Non-specific capture antibody (mouse IgG) was immobilized onto the surface of the SPGE instead of NS1 antibody. Control experiments were treated identically to the specific experiments from 0.5 ng/mL to 400 ng/mL and no significant changes were observed in the impedimetric responses. This demonstrated the specificity of the developed detection system.


Our latest laboratory results show that we can obtain results that match the performance of ELISA in under 15 minutes. We have tested our platform with different target molecules (eg. E. coli, cancer markers and dengue NS1), and have shown that our platform is equally efficient/independent of the target antibody/antigen target we use. 

All in all, the main advantage of the ELLI is that it shows qualitative and quantitative detection of NS1 protein down to a detection limit of 0.5 ng/mL involving an electrochemical signal based on a redox label ferrocene which is stable to both thermal and photobleaching. Moreover, a small volume of sample was also used and no enzymes were needed in the construction of the ELLI. The development and assembly of the ELLI is relatively simple, biocompatible, disposable, and inexpensive involving affordable technologies applying cellulose paper and screen printed electrodes thus providing POCT capabilities.

                                

Proof-of-principle of detecting clinically-relevant (picogram) concentrations of NT-proBNP using ELLI was done with at least twelve independent biofunctionalized SPGEs were used for each concentration of NT-proBNP, ranging from 100 pg/mL up to 5000 pg/mL, in duplicates. A drop of 50 µL NT-proBNP was applied during a 10-min incubation before the SPGE was washed with running dI water thoroughly (~10s). The SPGE was then slightly dried around its periphery and it is important to avoid contact with the electrodes surface. Afterwards, CV and EIS were performed sequentially. With an increase of NT-proBNP concentration, the current of redox reporter decreased while the resistance of the SPGE surface increased due to an increasing amount of NT-proBNP captured on the specific biofunctionalized SPGE.


For more detailed information check out our published peer-reviewed manuscripts:

Manuscript 1, Manuscript 2, Manuscript 3

The Offering

Investment
$10/share of Common Stock

$10.1 million post-money valuation

In the Press

PREVENTING STROKE AT HOME
June 1, 2018

Exclusive interview for SPINOFF.COM with Dr. Luka Fajs, Eclipse Diagnostics Inc., CEO, about blood-testing medical platform

Offering Summary


Company

:

Eclipse Diagnostics Inc.

Corporate Address

:

750 N. San Vicente Blvd, Los Angeles, CA 90069

Offering Minimum

:

$10,000.00

Offering Maximum

:

$1,070,000.00

Minimum Investment Amount

(per investor)

:

$500.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

1,000

Maximum Number of Shares Offered

:

107,000

Price per Share

:

$10.00

Pre-Money Valuation

:

$10,000,000.00











Perks*

All investors

Regular updates on our technology progress

$2,000+

Exclusive content and regular company updates -

Canabinox test prototype

$5,000+

Your place on the Technology Ambassadors Page of the website - Exclusive content and frequent company

updates –

Canabinox test prototype

1-year 'Casual' subscription to the Canabinox testing - FREE

$10,000+

Your place on the Technology Ambassadors Page of the website - Exclusive content and regular company

updates –

Canabinox test prototype

Invitation to our annual company VIP events.

1-year 'Basic' subscription to the Canabinox testing - FREE

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments and salaries; Any expense labeled “Administration Expenses” that is not strictly for administrative purposes; Any expense labeled “Travel and Entertainment”; Any expense that is for the purposes of inter-company debt or back payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$0.00 USD
$0.00 USD
Cash And Cash Equivalents
$0.00 USD
$0.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$0.00 USD
$0.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
$0.00 USD
$0.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Canabinox Mobile App Update

9 days ago


Mobile App Updates


Canabinox Mobile App has new updates available now. From today on with Canabinox Mobile Application you are able to:

- MEASURE your plant or product profile

- CHECK your history data and past measurements

- ORDER A NEW reader and testers



Stay tuned on our social media channels for more info:

Facebook: https://www.facebook.com/canabinox/

Instagram: https://www.instagram.com/canabinox/

Twitter: https://twitter.com/Canabinox1

Linkedin: https://www.linkedin.com/company/canabinox/


-Eclipse Diagnostics Team

Attending the Nanjing Tech Week 2019 in China

about 2 months ago


Nanjing Tech Week 2019


A successful week behind us! Thank you Nanjing Tech Week for having us we loved to share our knowledge and tech with all of you. We made great connections and met some amazing people. We shared and learned a lot. 

Till next year!


-Eclipse Diagnostics Team

Attending the Nanjing Tech Week 2019 in China

about 2 months ago


Nanjing Tech Week 2019


Another great day behind us in Nanjing, China at the Nanjing Tech Week 2019. 💚 

Our team had several interviews for the Chinese media and they loved our Technology.
Our co-founder Robert was also pitching at the StartUpGrind. 💚



Stay tuned on our social media channels for more info:

Facebook: https://www.facebook.com/canabinox/

Instagram: https://www.instagram.com/canabinox/

Twitter: https://twitter.com/Canabinox1

Linkedin: https://www.linkedin.com/company/canabinox/


-Eclipse Diagnostics Team

Attending the Nanjing Tech Week 2019 in China

about 2 months ago


Nanjing Tech Week 2019


Our team had a great first day at the Nanjing Tech Week 2019 in Nanjing, China. If you have a chance you are welcome to stop by our booth. We will also have an official presentation pitch about our tech. Stay tuned on our social media channels:

Facebook: https://www.facebook.com/canabinox/

Instagram: https://www.instagram.com/canabinox/

Twitter: https://twitter.com/Canabinox1

Linkedin: https://www.linkedin.com/company/canabinox/



-Eclipse Diagnostics Team

Our article for L.A. Cannabis News is out!

2 months ago


L.A. Cannabis News


Check out our new article for L.A. Cannabis News where we spoke about our technology and more.



Or follow the link: https://lacannabisnews.com/affordable-handheld-cannabis-testing-device/


-Eclipse Diagnostics 


At the BIO 2019 International Convention in Philadelphia

3 months ago


BIO 2019 International Convention


We had a great time at the BIO 2019 International Convention in Philadelphia where the cannabis tech gets its first representation at BIO International Convention thanks to Auxly Cannabis Group, Farkel and Panarea Partners.

Great presentation by Gabriela Cezar showing the cannabis biotechnology outlook for the future! 


-Eclipse Diagnostics


Are you a Cannabis Grower or you know some? Watch this!

3 months ago

How can you invest in Canabinox, How can you get Canabinox and more...


Our CEO Luka Fajs, sharing some additional information about our Cannabis testing device with our community. We welcome your feedback and comments!


Watch the video here:


Or go to  https://www.youtube.com/watch?v=O45jZY_xXXk


Thanks for funding the future.

-Eclipse Diagnostics Team

Why is Canabinox crucial for the Cannabis Industry?

3 months ago

Why would a Grower, Weed user or Hemp user use Canabinox?


Our CEO Luka Fajs, sharing some crucial information about our Cannabis testing device with our community. We welcome your feedback and comments!


Watch the video here:


Or go to  https://www.youtube.com/watch?v=gDFVVwvDFNk


Thanks for funding the future.

-Eclipse Diagnostics Team

We are closing our campaign!

10 months ago

Dear Investors!


We are closing our campaign and we would like to thank you for your support, your comments and your letters. We we will keep you updated on our progress as we move forward.


A Big Thank You From Eclipse Diagnostics!



Notice of Funds Disbursement

10 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Material Change in Offering

11 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the Eclipse Diagnostics offering. Here's an excerpt describing the specifics of the change:


Eclipse Diagnostics is extending their campaign for 60 days.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Eclipse Diagnostics @ ICMMI2018 in China

11 months ago

Our Cofounder prof. Robert S Marks presenting our technology at the ICMMI2018 in Macau, China. 

#preventstrokeathome

Notice of Funds Disbursement

11 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Funds Disbursement

about 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Notice of Material Change in Offering

about 1 year ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the Eclipse Diagnostics offering. Here's an excerpt describing the specifics of the change:


Eclipse Diagnostics Inc. has extended their campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Eclipse Diagnostics @ Asia Tech Podcast today!

about 1 year ago

At Asia Tech Podcast today with our CEO Luka Fajs. We talked about medical devices and quantified testing for patients at risk of stroke. #asiatechpodcast #preventstrokeathome
More info: https://www.startengine.com/eclipse-diagnostics

-EclipseDiagnostics


Eclipse Diagnostics accepts Bitcoin (BTC)

about 1 year ago

Hi everyone!

Delighted to announce that now, anyone can invest in our company using Bitcoin as a form of payment! 

Help us prevent stroke at home and save lives! Follow the link and invest: https://www.startengine.com/eclipse-diagnostics

#preventstrokeathome 


This new feature makes StartEngine the only FINRA-regulated funding portal to currently accept the cryptocurrency as a form of investment on its platform. Follow the link for more info:

https://www.businesswire.com/news/home/20180719005148/en/StartEngine-Accepts-Bitcoin-Regulation-Crowdfunding

-EclipseDiagnostics


Notice of Funds Disbursement

about 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Eclipse Diagnostics @ The Zero One Technology Festival in China

about 1 year ago

The Zero One Technology Festival in China was a great experience where we successfully shared and presented our project. Here you can see our Cofounder prof. Robert S Marks pitching our technology at the event. Shenzhen thank you for having us. 


-EclipseDiagnostics



Eclipse Diagnostics @ The Zero One Technology Festival in China Now!

about 1 year ago

The Zero One Technology Festival in Shenzhen China is happening right now till the 9th of July. You are invited to join our team on booth B-01-5 and see our lifesaving technology.

#preventstrokeathome



-EclipseDiagnostics

Eclipse Diagnostics @ The Zero One Technology Festival in China

about 1 year ago

Happy to announce our presence this year at The Zero One Technology Festival in Shenzhen, China. This is the world's first large-scale smart living carnival that touches the future in every aspect. It aggregates the latest smart living technology products from around the world to present a bright future for humanity. We will be there from July 5th to July 8th and our Cofounder Pof. Robert Marks will present our technology.

Welcome to join our pitch and booth!

See you there!

For more info, you can follow the link: https://www.mansinternational.com/zeroonetechfestival

 


-EclipseDiagnostics


Notice of Funds Disbursement

about 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Eclipse Diagnostics for Medical Design Briefs

about 1 year ago

Our Technology was just published in Medical Design Briefs that features exclusive coverage of the latest medical and bio-medical innovations from NASA, its industry partners, and other major players in medical R&D worldwide.

You can read the whole article in here https://www.medicaldesignbriefs.com/component/content/article/1104-mdb/news/29218-new-diagnostic-device-may-prevent-stroke-at-home


-EclipseDiagnostics

Eclipse Diagnostics's exclusive interview for SPINOFF.COM

about 1 year ago

Exclusive interview for SPINOFF.COM with our CEO and Cofounder Dr. Luka Fajs, about our blood-testing medical platform.  

You can read the whole Interview here: https://spinoff.com/hometest

#PREVENTSTROKEATHOME


-EclipseDiagnostics


Eclipse Diagnostics at StartEngine Demo Day!

about 1 year ago

Our CEO and Cofounder Luka Fajs Pitching our Project at #StartEngineDemoDay! Participants had a chance to submit live questions to Luka and get more information about our Mission! You can have a look in here.
#PreventStrokeAtHome


-EclipseDiagnostics

Amending our Securities Offering

about 1 year ago

Hello! Recently, a change was made to the Eclipse Diagnostics offering. Here's an excerpt describing the specifics of that change:


Eclipse Diagnostics Inc. has extended their campaign.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Eclipse Diagnostics at StartEngine Demo Day!

about 1 year ago

Next Thursday the 31st of May at 9:00 am - 11:00 am (PST)  Eclipse Diagnostics will join the StarteEngine Demo Day where you will have the opportunity to hear about our mission and submit live questions. 

Follow the link and register now https://signup.startengine.com/demoday?utm_source=LiteScape_Technologies_Inc 


-EclipseDiagnostics

Eclipse Diagnostics at Techconnect

over 1 year ago

Happy to announce that our Cofounder Prof. Robert S. Marks presented Eclipse Diagnostics at Techconnect conference in Anaheim this week. Follow the link for more details https://techconnectworld.com/World2018/ 


-EclipseDiagnostics

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Successful Presentation at StartEngine Summit ICO 2.0

over 1 year ago

We joined and enjoyed at the StartEngine Summit ICO 2.0 at the Fairmont Hotel in Santa Monica, CA. Our Team successfully presented our Project and met a lot of new collaboration opportunity. We work hard because we are committed to an affordable and accessible Medical Device that will Prevent Stroke at Home! #StrokeAwarenessMonth #PreventStrokeAtHome 

Check out our presentation!


Check out our best Moments!









Thanks for your Support.

-EclipseDiagnostics

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Presenting at StartEngine Summit ICO 2.0

over 1 year ago

We are proud to announce that we will be presenting Eclipse Diagnostics at the StartEngine Summit ICO 2.0 at the Fairmont Hotel in Santa Monica, CA. Check out our presentation at 3:50PM (PST). You can register now for the FREE livestream of the Summit; sign up here to get the link.

We welcome a new business advisor!

over 1 year ago

We are delighted to announce that we have a new advisor on board!



Dr. Joseph Mocanu is the founder and CEO of Verge Capital Management (Singapore). He was a Principal in Oliver Wyman’s Singapore office, leading life sciences and digital health across Asia. Areas of expertise include business model innovation, expanding access, consumer health, and investment strategies. Prior to this, Joseph worked in private equity, co-founded a medical device startup, and developed new cancer therapies as part of his academic research. Joseph holds a PhD in Medical Biophysics at the University of Toronto and an MBA from the Richard Ivey School of Business. 

In his spare time, Joseph advises, mentors and invests in digital health and medtech startups, sits on the Advisory Board of Galen Growth Asia, a regional digital health industry organisation, and is a startup mentor at the Singapore Institute of Management.


His expertise will help up with faster market entry, reimbursement strategies and business development.

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Amending our Securities Offering

over 1 year ago

Hello! Recently, a change was made to the Eclipse Diagnostics offering. Here's an excerpt describing the specifics of that change:


Eclipse Diagnostics Inc. is raising their maximum funding goal to $1,070,000.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Eclipse Diagnostics has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Eclipse Diagnostics be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}